Vanda Pharmaceuticals Statistics
Share Statistics
Vanda Pharmaceuticals has 58.93M
shares outstanding. The number of shares has increased by 0.2%
in one year.
| Shares Outstanding | 58.93M |
| Shares Change (YoY) | 0.2% |
| Shares Change (QoQ) | 0.01% |
| Owned by Institutions (%) | 73.65% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 94 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 4.66M, so 7.91% of the outstanding
shares have been sold short.
| Short Interest | 4.66M |
| Short % of Shares Out | 7.91% |
| Short % of Float | 9.54% |
| Short Ratio (days to cover) | 11.4 |
Valuation Ratios
The PE ratio is -14.74 and the forward
PE ratio is -10.87.
Vanda Pharmaceuticals's PEG ratio is
0.02.
| PE Ratio | -14.74 |
| Forward PE | -10.87 |
| PS Ratio | 1.4 |
| Forward PS | 0.7 |
| PB Ratio | 0.52 |
| P/FCF Ratio | -17.14 |
| PEG Ratio | 0.02 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Vanda Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.39,
with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.39 |
| Quick Ratio | 4.37 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | -0.38 |
| Debt / FCF | -0.76 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $540,141.3 |
| Profits Per Employee | $-51,358.7 |
| Employee Count | 368 |
| Asset Turnover | 0.3 |
| Inventory Turnover | 6.56 |
Taxes
| Income Tax | -4.02M |
| Effective Tax Rate | 17.54% |
Stock Price Statistics
The stock price has increased by -17.21% in the
last 52 weeks. The beta is 0.69, so Vanda Pharmaceuticals's
price volatility has been higher than the market average.
| Beta | 0.69 |
| 52-Week Price Change | -17.21% |
| 50-Day Moving Average | 4.41 |
| 200-Day Moving Average | 4.71 |
| Relative Strength Index (RSI) | 51.7 |
| Average Volume (20 Days) | 639,931 |
Income Statement
In the last 12 months, Vanda Pharmaceuticals had revenue of 198.77M
and earned -18.9M
in profits. Earnings per share was -0.33.
| Revenue | 198.77M |
| Gross Profit | 187.46M |
| Operating Income | -40.66M |
| Net Income | -18.9M |
| EBITDA | -32.53M |
| EBIT | -40.66M |
| Earnings Per Share (EPS) | -0.33 |
Full Income StatementBalance Sheet
The company has 102.32M in cash and 12.36M in
debt, giving a net cash position of 89.96M.
| Cash & Cash Equivalents | 102.32M |
| Total Debt | 12.36M |
| Net Cash | 89.96M |
| Retained Earnings | -174.29M |
| Total Assets | 631.94M |
| Working Capital | 303.99M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -15.76M
and capital expenditures -490K, giving a free cash flow of -16.25M.
| Operating Cash Flow | -15.76M |
| Capital Expenditures | -490K |
| Free Cash Flow | -16.25M |
| FCF Per Share | -0.28 |
Full Cash Flow StatementMargins
Gross margin is 94.31%, with operating and profit margins of -20.46% and -9.51%.
| Gross Margin | 94.31% |
| Operating Margin | -20.46% |
| Pretax Margin | -11.53% |
| Profit Margin | -9.51% |
| EBITDA Margin | -16.36% |
| EBIT Margin | -20.46% |
| FCF Margin | -8.17% |
